Condition

Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 5 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials5
Recruiting0
Common interventions10
Lead sponsors shown2
Advertisement

Clinical trials

5 shown
Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck CancerNCT01528137 · 2012-05-01
TERMINATED
Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung CancerNCT00101348 · 2005-01-01
COMPLETED
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid TumorsNCT00089362 · 2004-07-01
COMPLETED
Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and NeckNCT00063895 · 2003-04-01
COMPLETED
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuNCT00004074 · 1999-08-01
COMPLETED

Trial status mix

COMPLETED4
TERMINATED1

Phase mix

PHASE15
PHASE22

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.